correct - neutrophils usually make up to 50-70%% of circulating white blood cells and serve as the primary defense against infections by destroying bacteria in the blood. that is part of the blood test.
this all gets back to my guess that early blood tests for neutropenia and thrombocytopenia alerted the investigator to the unusual wonderful property of this compound and is prompting the inclusion of the first cohort in the second round of dosing.
the news is good - on that everyone seems to agree. we'll find out why exactly soon. it won't matter much in the long run to how the stock does. if it works we'll make money no matter what the reason.
News 
Market Data 
Discover 
AI
